Once SB is done and solving the priority of revenue, the BOT will need to pick it's next priority amongst its diverse pipeline of products.
One that remains extremely and increasingly relevant to the world is BOT's Antimicrobial studies via synthetic cannabinoids, which whilst partnered with University of Queensland, have demonstrated a novel mechanism for killing bacteria (unlike existing antibiotics).
news.com.au provides a frequent reminder of the war against antibiotic-resistant bacterial infections, which appears to continue to climb. Today it's shigellosis in Victoria (here).
So what? To new-comers joining BOT, the journey is far more than SB in September. The 'seed is only starting to sprout...'
I personally have a 5 year plan with this one which shall encompass numerous slam dunks, with an aim for achieving financial independence at the end of my tenure in this stock.
Enjoy the ride
dyor
BOT Price at posting:
14.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)